// App-Quantinova.ai

: Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Researchers

Presenter

  • Iryna Dekhtiarenko

Principal Investigators

  • Jan Attig

  • Nassim Sleiman

  • Domenico Lazzaro

  • Emilie Schindler

  • Jan Eckmann

  • Pablo Umana

  • Wolfgang Jacob

  • Meike Schneider

  • Carmelo Carlo-Stella

  • Rita Mazza

  • Salomon Manier

  • Thierry Facon

  • Sung-Soo Yoon

  • Youngil Koh

  • Simon J Harrison

  • Jeremy Er

  • Antonio Pinto

  • Francesco Volzone

  • Giulia Perrone

  • Paolo Corradini

  • Titouan Cazaubiel

  • Cyrille Hulin

  • Cyrille Touzeau

  • Philippe Moreau

  • Enrique M. Ocio

  • Carmen Maria Montes Gaisan

  • Rakesh Popat

  • Sarah Leong

  • Fritz Offner

  • Paula Rodriguez Otero

  • Ana Alfonso-Pierola

  • Martin Hutchings

  • Caroline Hasselbalch Riley

  • Ann-Marie E Bröske

Medical Centers

  • Department of Hematology, Clinica Universidad de Navarra, Navarra, Spain

  • Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

  • CHU de Nantes, Nantes, France

  • Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

  • CHU de BORDEAUX, BORDEAUX, France

  • Clínica Universidad de Navarra, Navarra, Spain

  • Seoul National University College of Medicine, Seoul, Korea, Republic of (South)

  • Hospital Universitario Marques de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain

  • Rigshospitalet, Copenhagen, Denmark

  • Department of Oncology and Hematology, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

  • Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, Australia

  • CHU de Lille, Lille, France

  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

  • Centre Hospitalier Universitaire (CHU) de Nantes, INSERM, Université de Nantes, Nantes, France

  • The Walter and Eliza Hall Institute of Medical Research and Department of Medical Biology, University of Melbourne, Melbourne, Australia

  • Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

  • Seoul National University Hospital, Seoul, Korea, Republic of (South)

  • IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Locations

  • Spain

  • France

  • Australia

  • Italy

  • United Kingdom

  • Republic of South Korea

  • Switzerland

  • Germany

  • Belgium

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Nucleoside diphosphate kinase A

  • Cluster of differentiation 8A

  • Syndecan-1

Drug/Treatment

  • Uliprisnil acetate

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved